162 related articles for article (PubMed ID: 27427904)
1. XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice.
Semenchenko K; Wasylyk C; Cheung H; Tourrette Y; Maas P; Schalken JA; van der Pluijm G; Wasylyk B
PLoS One; 2016; 11(7):e0159531. PubMed ID: 27427904
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules.
Wasylyk C; Zheng H; Castell C; Debussche L; Multon MC; Wasylyk B
Cancer Res; 2008 Mar; 68(5):1275-83. PubMed ID: 18316589
[TBL] [Abstract][Full Text] [Related]
3. Silencing of ELK3 Induces S-M Phase Arrest and Apoptosis and Upregulates SERPINE1 Expression Reducing Migration in Prostate Cancer Cells.
Mao Y; Li W; Hua B; Gu X; Pan W; Chen Q; Xu B; Wang Z; Lu C
Biomed Res Int; 2020; 2020():2406159. PubMed ID: 32104682
[TBL] [Abstract][Full Text] [Related]
4. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
[TBL] [Abstract][Full Text] [Related]
5. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.
Rabbani SA; Valentino ML; Arakelian A; Ali S; Boschelli F
Mol Cancer Ther; 2010 May; 9(5):1147-57. PubMed ID: 20423991
[TBL] [Abstract][Full Text] [Related]
6. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Aytes A; Mitrofanova A; Kinkade CW; Lefebvre C; Lei M; Phelan V; LeKaye HC; Koutcher JA; Cardiff RD; Califano A; Shen MM; Abate-Shen C
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):E3506-15. PubMed ID: 23918374
[TBL] [Abstract][Full Text] [Related]
7. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.
van der Horst G; van den Hoogen C; Buijs JT; Cheung H; Bloys H; Pelger RC; Lorenzon G; Heckmann B; Feyen J; Pujuguet P; Blanque R; Clément-Lacroix P; van der Pluijm G
Neoplasia; 2011 Jun; 13(6):516-25. PubMed ID: 21677875
[TBL] [Abstract][Full Text] [Related]
8. ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer.
Jiang J; Loganathan J; Eliaz I; Terry C; Sandusky GE; Sliva D
Int J Oncol; 2012 May; 40(5):1339-44. PubMed ID: 22293856
[TBL] [Abstract][Full Text] [Related]
9. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
10. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
12. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
Takeuchi A; Eto M; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Itsumi M; Naito S
Int J Oncol; 2012 May; 40(5):1691-6. PubMed ID: 22344606
[TBL] [Abstract][Full Text] [Related]
14. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer.
Chen WY; Liu SY; Chang YS; Yin JJ; Yeh HL; Mouhieddine TH; Hadadeh O; Abou-Kheir W; Liu YN
Oncotarget; 2015 Jan; 6(1):441-57. PubMed ID: 25436980
[TBL] [Abstract][Full Text] [Related]
16. A novel antitumor piperazine alkyl compound causes apoptosis by inducing RhoB expression via ROS‑mediated c‑Abl/p38 MAPK signaling.
Chung KS; Han G; Kim BK; Kim HM; Yang JS; Ahn J; Lee K; Song KB; Won M
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1315-24. PubMed ID: 24121479
[TBL] [Abstract][Full Text] [Related]
17. Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models.
Chen Y; Gera L; Zhang S; Li X; Yang Y; Mamouni K; Wu AY; Liu H; Kucuk O; Wu D
Cancer Lett; 2019 Apr; 446():62-72. PubMed ID: 30660650
[TBL] [Abstract][Full Text] [Related]
18. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
19. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
20. XRP44X Enhances the Cytotoxic Activity of Natural Killer Cells by Activating the c-JUN N-Terminal Kinase Signaling Pathway.
Kim KS; Park KS
Dev Reprod; 2020 Mar; 24(1):53-62. PubMed ID: 32411918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
